Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07501156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 18, 2026 to Jun 30, 2027v2 Show 4 more changesShow less
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study completion pushed from Apr 30, 2030 to Jun 30, 2030
    • Study description expanded, about 66 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.
Trial Details
NCT Number NCT07501156
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Related terms Diffuse Intrinsic Pontine Glioma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov